|
WO2016073889A1
(en)
|
2014-11-06 |
2016-05-12 |
Lysosomal Therapeutics Inc. |
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
|
|
EP3215511B1
(en)
|
2014-11-06 |
2024-04-17 |
Bial-R&D Investments, S.A. |
Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
|
|
US20180185368A1
(en)
|
2014-11-06 |
2018-07-05 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
WO2017176961A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
MX388912B
(es)
|
2016-04-06 |
2025-03-20 |
Lysosomal Therapeutics Inc |
Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
|
|
KR20180133461A
(ko)
|
2016-04-06 |
2018-12-14 |
리소소말 테라퓨틱스 인크. |
피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
|
|
WO2017192930A1
(en)
*
|
2016-05-05 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
US10836770B2
(en)
|
2016-10-07 |
2020-11-17 |
Bristol-Myers Squibb Company |
Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
|
|
US11299494B2
(en)
*
|
2016-11-17 |
2022-04-12 |
Bristol-Myers Squibb Company |
Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
|
|
IL317854A
(en)
*
|
2017-07-28 |
2025-02-01 |
Takeda Pharmaceuticals Co |
TYK2 inhibitors and their uses
|
|
TW201940483A
(zh)
|
2018-03-12 |
2019-10-16 |
美商艾伯維有限公司 |
酪胺酸激酶２介導的傳訊之抑制劑
|
|
EP3849981B1
(en)
|
2018-09-10 |
2023-02-01 |
Eli Lilly and Company |
Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
|
|
RS66346B1
(sr)
|
2018-10-22 |
2025-01-31 |
Alumis Inc |
Inhibitori tyk2 i njihova upotreba
|
|
TWI800696B
(zh)
*
|
2018-12-10 |
2023-05-01 |
美商美國禮來大藥廠 |
7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
|
|
TWI752400B
(zh)
*
|
2019-01-07 |
2022-01-11 |
美商美國禮來大藥廠 |
Il-17a抑制劑
|
|
CA3126034A1
(en)
|
2019-01-23 |
2020-07-30 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
SG11202108619SA
(en)
*
|
2019-02-07 |
2021-09-29 |
Ventyx Biosciences Inc |
Tyk2 pseudokinase ligands
|
|
KR102865925B1
(ko)
*
|
2019-03-05 |
2025-09-26 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
|
|
US20220177486A1
(en)
*
|
2019-03-11 |
2022-06-09 |
Esker Therapeutics, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CA3167313A1
(en)
|
2020-02-12 |
2021-08-19 |
Thomas John Bleisch |
Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
|
|
TWI810520B
(zh)
|
2020-02-12 |
2023-08-01 |
美商美國禮來大藥廠 |
7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
|
|
JP7664947B2
(ja)
*
|
2020-04-30 |
2025-04-18 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｉｌ－１７の調節因子としてのイミダゾリダジン
|
|
US12559496B2
(en)
|
2020-04-30 |
2026-02-24 |
Janssen Pharmaceutica Nv |
Imidazopyrimidines as modulators of IL-17
|
|
EP3944859A1
(en)
|
2020-07-30 |
2022-02-02 |
Assistance Publique Hôpitaux de Paris |
Method for treating immune toxicities induced by immune checkpoint inhibitors
|
|
CN115916207A
(zh)
*
|
2020-08-20 |
2023-04-04 |
轶诺(浙江)药业有限公司 |
一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
|
|
IL301385A
(en)
*
|
2020-09-16 |
2023-05-01 |
Alumis Inc |
TYK2 inhibitors and their use
|
|
CN117043164A
(zh)
*
|
2021-01-19 |
2023-11-10 |
安锐生物医药科技(广州)有限公司 |
咪唑并哒嗪或吡唑并嘧啶化合物和组合物
|
|
EP4308556A4
(en)
|
2021-03-16 |
2025-02-19 |
Anrui Biomedical Technology (Guangzhou) Co., Ltd. |
Amino heteroaryl compounds and compositions
|
|
KR20240111312A
(ko)
|
2021-10-25 |
2024-07-16 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Tyk2 분해제 및 이의 용도
|
|
CN118580191A
(zh)
*
|
2022-01-28 |
2024-09-03 |
和记黄埔医药（上海）有限公司 |
用于制备咪唑并[1,2-b]哒嗪类化合物的中间体
|
|
WO2025168035A1
(zh)
*
|
2024-02-07 |
2025-08-14 |
合肥羿科医药有限公司 |
杂环类化合物、其药物组合物及其应用
|